Currently responsible for running NICE’s technology appraisal and highly specialised technologies programmes, Meindert has a strong track record in health technology evaluation, occupying a senior technical and leadership role in NICE’s drug appraisal programme.
Before joining NICE in 2004 Meindert worked for Eli Lilly in the Netherlands, and for the King’s Fund in London after graduating with an MSc in Health Policy Planning and Financing from the London School of Economics & Political Sciences.
Meindert will take over from Mirella Marlow, the Centre’s acting Director, and succeeds Professor Carole Longson, who left NICE earlier this month after 17 years in the post.
Sir Andrew Dillon, NICE chief executive, said: “I am delighted that Meindert has been appointed as NICE’s director of the Centre for Health Technology Evaluation.
“Meindert has the skills and experience, and the leadership qualities that will be important in maintaining NICE’s global position at the forefront of health technology evaluation.”
Meindert Boysen, currently programme director for the NICE Centre for Health Technology Evaluation, said: “It is a great honour to have been asked to lead the teams that together make up the Centre for Health Technology Evaluation at NICE. Over the many years of having worked in this field, I have been truly impressed with the skills, experience and dedication of all those involved in ensuring that NICE guidance adds the value that so many expect of it.
“I look forward to working with colleagues in the life sciences industry, patients, clinicians and commissioners on making the journey through NICE, and the related programmes in NHS England, as smooth as possible. Delivering on the expectations raised by the Accelerated Access Review and the Life Sciences Industrial Strategy is a joint responsibility of all working to support access to worthwhile, innovative, technologies; it will definitely be my top priority.”